Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases - Test2 - elhamkhani - TriplyDB

Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases

Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases

http://www.wikidata.org/entity/Q27022636

about

Long-acting muscarinic antagonist plus long-acting beta agonist versus long-acting beta agonist plus inhaled corticosteroid for stable chronic obstructive pulmonary disease Aclidinium bromide for stable chronic obstructive pulmonary disease Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).Responsiveness to Ipratropium Bromide in Male and Female Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease.Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells.Cholinergic Targets in Lung Cancer Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium.Interactions between glycopyrronium and indacaterol on cholinergic neurotransmission and contractile response in bovine trachealis.The influence of type of inhalation device on adherence of COPD patients to inhaled medication.How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?Safety of inhaled long-acting anti-muscarinic agents in COPD.Differences in Adherence to Common Inhaled Medications in COPD.Tiotropium bromide exerts anti-inflammatory effects during resistive breathing, an experimental model of severe airway obstruction.Distribution and function of the muscarinic receptor subtypes in the cardiovascular system.Management of Severe Asthma before Referral to the Severe Asthma Specialist.A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD.Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies.Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.

P2860

Q24186227-00170B5F-9C35-4C5E-B948-958498776647 Q24193506-44BC9C5E-3C35-4D0A-8C73-B2E6F3C45C8C Q30238494-0E102802-F0E7-4F02-80F0-078836F5813B Q33715834-11B894E2-C996-4D65-A6BE-90BDC3E9E160 Q37001907-E5407372-61C9-4A68-BF9B-E347B01ACDF4 Q37127226-FA0A216B-C045-4865-B5EC-C029230CF90E Q38344780-25D97371-C1DA-4A36-893C-6EC12DCBC53E Q38654745-5FAFEE68-B825-4500-944B-1E866BC86B51 Q38932081-E6CD60C5-AD01-4339-9059-692D2DAC7221 Q39030602-A91C869C-6E2A-4CB4-8ADC-0D7AA44EF5C1 Q39232425-A95D34C6-271A-4BD2-9DEA-8FF8CB8997A4 Q41211645-B6CD09B6-B562-4144-AAE7-28E37F1F83D6 Q41276617-5900D12E-85F9-462F-BE2E-27D2B2B253C0 Q47576742-D4E7A994-CA97-4316-8686-58D15138BED4 Q52583301-6A11E698-AFA2-4C13-9136-72942CE71012 Q53839703-B8DB55F9-FB18-452C-AFD6-AB14C478248F Q55133367-1E26E190-4953-4342-B7FA-57F794DDE755 Q55364939-113E5FC5-09E1-420E-81A3-0A0037DA3666

P2860

Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases

http://www.wikidata.org/entity/Q27022636

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases

@ast

Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases

@en

Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases

@nl

type

label

Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases

@ast

Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases

@en

Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases

@nl

prefLabel

Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases

@ast

Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases

@en

Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases

@nl

P1433

Q27022636-8950D6CF-E31F-43AE-9F48-96C0BF7B4484

P1476

Q27022636-F4589CB3-216C-488D-AE81-1C28C37185CC

P2093

Q27022636-110C9A2E-29DB-4255-9C68-E2A952E24348

Q27022636-507E8763-8892-4965-9F17-C82936BEC4C8

Q27022636-545A6797-21C4-4B0F-B14D-B48F78164280

Q27022636-572AF241-C863-4AFF-8A66-BFD2A0F31C1D

Q27022636-8C9E307B-84A5-43A5-9FE9-0555E52C47D3

Q27022636-9EBA6FBC-41AC-4A06-AC47-390AA6BEBA77

Q27022636-A879F447-728A-41E1-B5DF-039F7F0EA783

Q27022636-A934057A-87D8-459F-BF0A-0E2BF7AAD4C2

Q27022636-CA567619-F77C-4B8F-862A-A4E052990FA3

Q27022636-CC588FDD-F4C2-44D3-955E-D0B668FDF163

P2860

Q27022636-02E212FE-16CD-4002-9AF1-547D90373BB1

Q27022636-04062431-9590-4E28-9313-80D9358EDD7F

Q27022636-065DC6F1-E0D4-44BF-80FA-800520D36306

Q27022636-0A73611E-B1CB-4FB2-AB2A-7A58379681E2

Q27022636-122DBB94-9894-4448-915E-32C2617DB51A

Q27022636-1606113F-31C1-4678-AB45-8EA299EAAA12

Q27022636-1D8A3682-4E6A-4FC5-91F0-4DF1F29EDD75

Q27022636-233CA5CB-8E00-4E74-81FE-2E8AB1CC571F

Q27022636-27541012-0C6E-4201-BCD9-54D0FFCDB4B8

Q27022636-2C41B74D-2F65-4647-AE40-F8F721A8909C

P304

Q27022636-4520D287-177E-4ED6-A24D-2CBF3690ABE8

P31

Q27022636-DCBE24D1-266C-408C-B697-7D31542106F8

P3181

Q27022636-B663DF12-341E-4126-B2E9-FB45DD4F4274

P356

Q27022636-AE8B708A-C9ED-48AE-AE12-DD69072E006C

P407

Q27022636-D2407631-F2FF-43D1-8DFF-BBAFB7FC24C4

P433

Q27022636-04DAF223-FED0-4F1C-892E-A60E72637033

P478

Q27022636-7E5A54E6-2037-4D39-93D8-9D130B85A9F6

P577

Q27022636-75747FF7-709C-4884-AA5B-CCD016387D1D

P698

Q27022636-69E5C6CA-B523-4991-8E52-651E67D0355B

P932

Q27022636-6501FB8C-362B-4B29-8A44-D6ACCFE10C29

P3181

P356

2040622313518227

P1433

Therapeutic advances in chronic disease

P1476

Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases

@en

P2093

A. Bourdin

http://www.w3.org/2001/XMLSchema#string

A. Palot

http://www.w3.org/2001/XMLSchema#string

C. Tummino

http://www.w3.org/2001/XMLSchema#string

D. Charpin

http://www.w3.org/2001/XMLSchema#string

K. Alagha

http://www.w3.org/2001/XMLSchema#string

L. Pahus

http://www.w3.org/2001/XMLSchema#string

M. Gouitaa

http://www.w3.org/2001/XMLSchema#string

P. Chanez

http://www.w3.org/2001/XMLSchema#string

S. Martinez

http://www.w3.org/2001/XMLSchema#string

T. Sofalvi

http://www.w3.org/2001/XMLSchema#string

P2860

Tiotropium versus placebo for chronic obstructive pulmonary disease

Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials

The nature of small-airway obstruction in chronic obstructive pulmonary disease

Motor control of airway goblet cells and glands.

Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor.

Tiotropium bromide inhibits TGF-β-induced MMP production from lung fibroblasts by interfering with Smad and MAPK pathways in vitro

Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials.

Tiotropium bromide step-up therapy for adults with uncontrolled asthma

Remodeling in asthma and chronic obstructive lung disease.

Inhibition of granulocyte migration by tiotropium bromide

P304

85-98

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

830078

http://www.w3.org/2001/XMLSchema#string

P356

10.1177/2040622313518227

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24587893

http://www.w3.org/2001/XMLSchema#string

P932

3926345

http://www.w3.org/2001/XMLSchema#string